The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The U.S. Food and Drug Administration has missed its deadline for making a decision on traditional approval for Novavax's ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

The US drug regulator has missed a deadline for granting full approval to Novavax's COVID-19 vaccine, the company said ...

The FDA delays full approval for Novavax's COVID-19 vaccine, citing the need for additional data. Read more here.

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

The Novavax vaccine, which uses more traditional protein-based technology than the newer mRNA vaccines from Pfizer/BioNTech and Moderna, has been subject to emergency use authorization since 2022.

The US Food and Drug Administration was supposed to make a final decision about whether or not to approve Novavax's (NVAX) COVID-19 vaccine this week, but that deadline has passed with no clarity ...

The U.S. Food and Drug Administration has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...